Jump to: navigation, search

Radboud Imaging Research

Welcome to the research website of the Department of Radiology and Nuclear Medicine at Radboud university medical center, Nijmegen.

Our research has a strong focus on early detection and early treatment of common diseases. It covers fundamental research on a molecular level, development of new medical devices and software tools, and translates these results to clinical applications that can be used in daily routine. Our mission is to bridge the gap between research and practice and to help shape the future of healthcare. We use technology to make healthcare more affordable by increasing automation of diagnostic and therapeutic procedures, thus freeing manpower for those areas in patient care in which the "human touch" is most needed.

The four fundamental science groups cover ultrasound (MUSIC), biomedical MR (BioMR), diagnostic image analysis (DIAG) and tracer research (TRACER). Clinical research is mainly focused on prostate, breast, chest and vascular disease.

With the menu on the right you can learn more about our researchers, view or download publications or navigate to any of the research groups within the department.



Prof. Arend Heerschap and dr. William Leenders have published a paper in Cancer Research entitled: IDH1 R132H mutation generates a distinct phospholipid metabolite profile in gliomas.

Many glioma patients harbor specific mutations in the isocitrate dehydrogenase gene IDH1, which associate with a relatively better prognosis. IDH1-mutated tumors produce the oncometabolite 2-hydroxyglutarate. Since IDH1 regulates several pathways leading to lipid synthesis, they hypothesized that IDH1 mutant tumors would display an altered phospholipid metabolite profile which would impinge on tumor pathobiology. Their results provide evidence that the IDH1-R132H mutation alters phospholipid metabolism in gliomas involving phosphoethanolamine and glycerophosphocholine. These new noninvasive biomarkers can assist in the identification of the mutation and in research toward novel treatments that target aberrant metabolism in IDH1-mutant glioma. To read the full article, please click here.

See more in the Highlight Archive.


For older news, see the News Archive.